EUVIMEDEUVIMED entdecken
Übersichtsarbeit

AZP2006 (Ezeprogind ® ): a Promising New Drug Candidate in the Battle Against Neurodegenerative Diseases

Philippe Verwaerde iD, Olivier Defert iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400891 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, 2025. Verfasst von Philippe Verwaerde und 1 weiteren Autor:innen. Beteiligte Einrichtung: Alzprotect SAS, 85 C rue Nelson Mandela, 59120, Loos, France. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Supranuclear Palsy, Progressive, Neuroprotective Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder characterized by abnormal tau protein accumulation. This perspective article explores AZP2006 (INN: Ezeprogind), a novel small molecule targeting the Progranulin (PGRN) and Prosaposin (PSAP) axis to enhance lysosomal health in PSP treatment. AZP2006 stabilizes the PGRN‐PSAP complex, improving lysosomal function and reducing tau pathology. Preclinical studies in tauopathy models demonstrated AZP2006′s ability to decrease tau hyperphosphorylation, enhance neuronal survival, mitigate neuroinflammation and promote synaptogenesis. Clinical trials have shown AZP2006 to be well‐tolerated in healthy volunteers and PSP patients. A Phase 2a study met its primary endpoints, as it provided valuable safety data and even encouraged further investigation of its efficacy in a larger clinical study. An upcoming Phase 2b/3 trial aims to assess long‐term safety and efficacy in a larger PSP cohort. AZP2006′s mechanism of action strongly suggests potential applications in other tauopathies, including Alzheimer's and Parkinson's diseases. By addressing lysosomal dysfunction and tau pathology, AZP2006 represents a promising disease‐modifying approach for PSP and other neurodegenerative disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurodegenerative DiseasesSupranuclear Palsy, ProgressiveNeuroprotective AgentsHumansAnimalsSaposinsProgranulinstau Proteins

Stichwörter der Autor:innen

AZP2006NeurodegenerationProgranulinProgressive Supranuclear PalsyTauopathies

Substanzen

SaposinsProgranulinstau ProteinsNeuroprotective AgentsPSAP protein, human

Autor:innen und Institutionen

  • Alzprotect SAS, 85 C rue Nelson Mandela, 59120, Loos, France.

ORCID-Profile: Philippe Verwaerde, Olivier Defert

Zitieren

APA

Verwaerde, P., & Defert, O. (2025). AZP2006 (Ezeprogind ® ): a Promising New Drug Candidate in the Battle Against Neurodegenerative Diseases. ChemMedChem. https://doi.org/10.1002/cmdc.202400891

Vancouver

Verwaerde P, Defert O. AZP2006 (Ezeprogind ® ): a Promising New Drug Candidate in the Battle Against Neurodegenerative Diseases. ChemMedChem. 2025. doi:10.1002/cmdc.202400891

BibTeX
@article{Verwaerde2025,
  author = {Verwaerde, Philippe and Defert, Olivier},
  title = {AZP2006 (Ezeprogind ® ): a Promising New Drug Candidate in the Battle Against Neurodegenerative Diseases},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400891}
}
Kostenlos starten →